Two developments on the stock markets have stood out since the beginning of the year: rising inflation expectations and significant increases in government bond yields. Could market sentiment soon turn frosty in view of this?
LATEST CONTRIBUTIONS
Trump’s tariff plans: a game with no winners?
On 20 January, the world will once again look to Washington with anticipation as Donald Trump is sworn in as US President for the second time in front of the Capitol. In any case, his statements and plans are already the focus of attention on the financial markets.
Trump is planning high import tariffs for goods, for example from Mexico and China. The possible consequences range from the threat of a trade war to a comeback of inflation. In the end, will no one benefit from the planned tariff measures?
Best of Charts: What’s coming, what’s going, what’s staying from 2024?
We can look back on an eventful year on the markets – although 2025 is also off to a somewhat turbulent start (at least in terms of domestic politics). In our first ‘Best of Charts’ of the new year, we look at what will remain of the stock market year 2024 and what we can expect in the coming months.
China prepares economic stimulus package in response to recession and looming trade war
The former growth engine China is having trouble getting back on track. Geopolitical tensions, the crisis in the domestic real estate sector and weak domestic consumption are hampering the country’s economy.
The government in Beijing is using billions in support measures not only to counter the economic downturn, but also to brace itself against the tariffs announced by US President-elect Donald Trump. But can these measures also help the faltering Chinese stock market?
Pharmaceutical Companies Increase Sales, Focus on Innovation and Acquisitions
The pharmaceutical industry was able to further increase its sales in the last quarter. The biggest players in the sector are relying on acquisitions and innovations – including the increased use of AI. However, things could get more uncomfortable for pharmaceutical companies in the US market: the future US Secretary of Health and Human Services, Rober F. Kennedy Jr., is considered a critic of the industry and has already spoken out in favor of capping drug prices.
The ethical business case: What is the case for ESG?
Climate protection has long since arrived in the financial industry. Even though there has recently been political headwind for ESG in some countries, the topic remains important for investors. This is because taking sustainability factors into account makes sense for companies in a number of ways. You can find out more about this in the article.
Know-How
Decision to invest taken – what happens next?
As an investor, you will come across several parties or institutions in the fund selection and securities account opening process.
Markets
Trump’s tariff plans: a game with no winners?
On 20 January, the world will once again look to Washington with anticipation as Donald Trump is sworn in as US President for the second time in front of the Capitol. In any case, his statements and plans are already the focus of attention on the financial markets.
Trump is planning high import tariffs for goods, for example from Mexico and China. The possible consequences range from the threat of a trade war to a comeback of inflation. In the end, will no one benefit from the planned tariff measures?
Sustainability
The ethical business case: What is the case for ESG?
Climate protection has long since arrived in the financial industry. Even though there has recently been political headwind for ESG in some countries, the topic remains important for investors. This is because taking sustainability factors into account makes sense for companies in a number of ways. You can find out more about this in the article.
Equities
Pharmaceutical Companies Increase Sales, Focus on Innovation and Acquisitions
The pharmaceutical industry was able to further increase its sales in the last quarter. The biggest players in the sector are relying on acquisitions and innovations – including the increased use of AI. However, things could get more uncomfortable for pharmaceutical companies in the US market: the future US Secretary of Health and Human Services, Rober F. Kennedy Jr., is considered a critic of the industry and has already spoken out in favor of capping drug prices.
Bonds
Sovereign defaults and their debt restructuring
A glance at history shows that it is not unheard of for a state to go bankrupt. How does an entire country actually go bankrupt, what are the consequences and how do you react to this in fund management? Fund manager Felix Dornaus explains this in his blog post.